A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Infection.

Trial Profile

A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Vaniprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 28 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 04 Jan 2012 Actual patient number changed from 176 to 182 as reported by ClinicalTrials.gov.
    • 29 Oct 2010 Final efficacy and tolerability results presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top